FDA's Ongoing User Fee System Upgrade Limits Payment Options
This article was originally published in The Pink Sheet Daily
But it comes at a time when there is traditionally a lull in filings of generic drug applications.
You may also be interested in...
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
Fee structure changes and process enhancements floated during opening session between industry and agency.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.